AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Berenberg Bank in a research report issued on Monday, Marketbeat reports. They currently have a GBX 140 ($1.74) price target on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential downside of 98.75% from the company’s previous close.
AZN has been the topic of a number of other reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a £140 ($174.19) target price on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($98.74).
Get Our Latest Stock Analysis on AZN
AstraZeneca Price Performance
Insiders Place Their Bets
In other news, insider Pascal Soriot bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were bought at an average cost of £102.03 ($126.95) per share, for a total transaction of £2,040,600 ($2,539,007.09). Also, insider Tony Mok purchased 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average price of £126.80 ($157.77) per share, with a total value of £190,200 ($236,655.47). Company insiders own 0.04% of the company’s stock.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Recommended Stories
- Five stocks we like better than AstraZeneca
- Financial Services Stocks Investing
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Stock Splits, Do They Really Impact Investors?
- What Does the Future Hold for Eli Lilly?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.